Valuation: Avacta Group Plc

Market Cap 311M 419M 364M 339M 588M 40.03B 597M 4B 1.57B 19.93B 1.57B 1.54B 66.82B P/E 2026 *
-9.51x
P/E 2027 * -9.8x
Enterprise Value 306M 412M 358M 333M 578M 39.31B 587M 3.93B 1.54B 19.57B 1.55B 1.51B 65.62B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.8%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

1 day-2.06%
1 week-5.00%
1 month-8.28%
3 months-11.33%
6 months+34.34%
Current year+14.66%
1 week 66
Extreme 66
70
1 month 66
Extreme 66
74
Current year 48
Extreme 48
92
1 year 41.33
Extreme 41.33
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Date Insider Type Main position Quantity % Market Cap.
9/2/24 A Sell

Chief Financial Officer

500,000 0.1393%
9/2/24 A Free

Chief Executive Officer

3,600,000 1.0027%
9/2/24 A Fiscal year

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%-5.00%+41.49%-32.49% 419M
+2.35%+2.74%+38.10%+74.02% 56.54B
-0.21%-7.38%+27.52%+63.59% 53.6B
-2.44%+1.40%-15.61%-13.72% 22.91B
-2.85%-7.78%-9.28%+352.92% 21.37B
-0.72%-0.41%+23.32%-15.10% 20.27B
+0.79%-1.06%+33.99%-30.63% 17.56B
-2.44%-8.04%+16.82%+548.18% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
-5.25%-4.23%+42.32%+160.72% 13.33B
Average -0.93%-3.91%+36.15%+139.53% 23.43B
Weighted average by Cap. -0.23%-2.96%+30.63%+119.88%

Financials

2026 *2027 *
Net sales - -
Net income -33.4M -44.97M -39.09M -36.38M -63.08M -4.29B -64.06M -429M -168M -2.14B -169M -165M -7.17B -32.74M -44.07M -38.31M -35.66M -61.82M -4.21B -62.78M -420M -165M -2.09B -165M -162M -7.02B
Net Debt -5.58M -7.51M -6.53M -6.08M -10.53M -717M -10.7M -71.61M -28.1M -357M -28.2M -27.58M -1.2B 21.72M 29.23M 25.41M 23.65M 41.01M 2.79B 41.65M 279M 109M 1.39B 110M 107M 4.66B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
31/07/26 GBX 66.50 -2.06% 1,172,213
30/07/26 GBX 67.90 -1.59% 604,391
29/07/26 GBX 69.00 +0.73% 777,240
28/07/26 GBX 68.50 -0.72% 505,358
27/07/26 GBX 69.00 -1.43% 862,574
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6650GBP
Average target price
0.8167GBP
Spread / Average Target
+22.81%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock